UNSPSC 51311807: Clemizole hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H20ClN3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85W6I13D8M, chemically known as benzimidazole, 1-(p-chlorobenzyl)-2-(1-pyrrolidinylmethyl)-, monohydrochloride but more generally known as clemizole hydrochloride, which bears US NIH Compound Identifier 14412. European Medicines Agency schedules Clemizole hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01336MIG.

UNSPSC 51311807 Clemizole hydrochloride is a Commodity code that in practice captures pharmaceutical procurement by state and local health agencies, though recent state and local solicitations tagged with this code diverge significantly from the product itself—the opportunities actually reflect purchase of naloxone, generic multi-source pharmaceuticals, OTC products, and direct-to-manufacturer prescription programs rather than clemizole hydrochloride specifically. State and local buyers under this code span county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The work involves acquisition of finished pharmaceutical products, bulk generic medications, and specialty health interventions delivered through established pharmaceutical distribution channels, with vendors required to meet cGMP certification, FDA compliance, drug supply chain security requirements, and insurance thresholds ranging from $2 million to $5 million in commercial general liability coverage.

Recent activity appears concentrated in Florida and Minnesota, with participation from the Texas Health and Human Services Commission. The Seminole County, Florida procurement (IFB 60459723LAS, response due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term with one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with pricing evaluation weighted 75 percent on competitiveness and products required to be available in the marketplace by May 15, 2026. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. The mismatch between the clemizole hydrochloride code designation and the actual pharmaceutical procurement activity suggests either cataloging drift or broad code application across generic pharmaceutical commodities.